Pharma donors favor Obama

Share this article:

Pharmaceutical industry execs have contributed more than three times as much to the Obama campaign as they have to McCain's, according to a Bloomberg News report citing data from the Center for Responsive Politics.

Sen. Obama has received $450,094 in donations from industry execs and employees, compared with $132,575 received by Sen. McCain -- even though 52% of industry donations have gone to Republicans in this cycle and industry donors overwhelmingly supported President Bush in the last presidential election, giving him nearly twice as much as they did John Kerry. 

Republican lobbyist John Feehery told Bloomberg that a lack of pharma donations for McCain may help him in the general election.  “He does go after these companies and they don't like it.  This solidifies McCain's reputation as someone who fights special interests,” Feehery said in the piece.

McCain's stance in favor of reimportation of drugs from Canada is a particular sore point for the industry. The Arizona Republican has also proposed sharply scaling back the Medicare prescription drug benefit, which drug companies pushed hard for.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...